Kala Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Kala Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014089
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kala Pharmaceuticals Inc (Kala Pharmaceuticals) is a clinical stage pharmaceutical company which focuses on nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. The company’s lead program MPP nanosuspension of an ophthalmic corticosteroid is under phase III clinical development for the treatment of post-surgical inflammation, ocular inflammation, meibomian gland disease and dry eye disease. Kala Pharmaceuticals is also developing a small molecule receptor tyrosine kinase inhibitor (RTKi) program for the treatment of wet age-related macular degeneration (AMD). The company is funded by life science investors such as Cam Capital, Longitude Capital Management, Lux Capital Management, RA Capital Management, Third Rock Ventures and others. Kala Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.

Kala Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Kala Pharma Raises USD68 Million in Series C Financing Round 10
Kala Pharma Raises USD7 Million in Venture Financing 12
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 13
Kala Pharma Raises US$11.5 Million In Series A Financing 15
Kala Pharma Raises US$6.2 Million In Seed Financing 17
Equity Offering 18
Kala Pharma Raises USD103.5 Million in IPO 18
Kala Pharmaceuticals Inc – Key Competitors 20
Kala Pharmaceuticals Inc – Key Employees 21
Kala Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Nov 07, 2017: Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update 23
Corporate Communications 25
Nov 13, 2017: Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer 25
Oct 02, 2017: Kala Pharmaceuticals Appoints Andrew I. Koven to Board of Directors 26
Product Approvals 27
Oct 25, 2017: Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYS (KPI-121 1%) 27
Clinical Trials 28
May 01, 2017: Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery 28
Jan 06, 2017: Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kala Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Kala Pharma Raises USD68 Million in Series C Financing Round 10
Kala Pharma Raises USD7 Million in Venture Financing 12
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 13
Kala Pharma Raises US$11.5 Million In Series A Financing 15
Kala Pharma Raises US$6.2 Million In Seed Financing 17
Kala Pharma Raises USD103.5 Million in IPO 18
Kala Pharmaceuticals Inc, Key Competitors 20
Kala Pharmaceuticals Inc, Key Employees 21

★海外企業調査レポート[Kala Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mediware Information Systems Inc-医療機器分野:企業M&A・提携分析
    Summary Mediware Information Systems Inc (Mediware) is a healthcare solutions company that designs, develops and commercializes specialized healthcare software. It provides software to healthcare and human service providers and payers. The company’s portfolio of solutions are equipped in blood banks …
  • Trican Well Service Ltd (TCW):石油・ガス:M&Aディール及び事業提携情報
    Summary Trican Well Service Ltd (Trican) is an oilfield services company, which provides specialized products, equipment, services and technology for use in the drilling, completion, stimulation and reworking of oil and gas wells. Its specialized services comprise fracturing, cementing, coiled tubin …
  • Commercial Metals Co:企業の戦略・SWOT・財務分析
    Commercial Metals Co - Strategy, SWOT and Corporate Finance Report Summary Commercial Metals Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Syngen Biotech Co Ltd (8279):製薬・医療:M&Aディール及び事業提携情報
    Summary Syngen Biotech Co Ltd (Syngen) is a biotechnology company. The company manufactures and supplies active pharmaceutical ingredients (APIs), biology fermentation products, nutritional ingredients, nutraceutical ingredients, biology agriculture and aquaculture products, and functional food prod …
  • IBIDEN CO., LTD.:企業の戦略・SWOT・財務情報
    IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report Summary IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • The Whiting-Turner Contracting Co:企業の戦略・SWOT・財務分析
    The Whiting-Turner Contracting Co - Strategy, SWOT and Corporate Finance Report Summary The Whiting-Turner Contracting Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Ingram Micro Inc.:企業の戦略・SWOT・財務情報
    Ingram Micro Inc. - Strategy, SWOT and Corporate Finance Report Summary Ingram Micro Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • GP Strategies Corp (GPX):企業の財務・戦略的SWOT分析
    Summary GP Strategies Corp (GP Strategies) is a performance improvement company that offers sales and technical training, eLearning solutions, management consulting, and engineering services. The company offers solutions such as human capital management, managed learning services, off the shelf offe …
  • Vericel Corp (VCEL):企業の財務・戦略的SWOT分析
    Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • GS Energy Corp-エネルギー分野:企業M&A・提携分析
    Summary GS Energy Corp (GS Energy) is an energy holding company that manufactures and markets transportation fuels. The company's services include exploration and production, green growth, gas and electric power, refining and petrochemicals. It's refining and petrochemicals services comprise manufac …
  • GATX Corp (GATX):企業の財務・戦略的SWOT分析
    GATX Corp (GATX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Oriental Land Co., Ltd. (4661):企業の財務・戦略的SWOT分析
    Oriental Land Co., Ltd. (4661) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • People’S Bank
    People'S Bank - Strategy, SWOT and Corporate Finance Report Summary People'S Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • GF Securities Co., Ltd. (1776):企業の財務・戦略的SWOT分析
    GF Securities Co., Ltd. (1776) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Leukocare AG-製薬・医療分野:企業M&A・提携分析
    Summary Leukocare AG (Leukocare) is a clinical stage biotechnology company that offers technologies for stabilizing proteins to increase shelf-life and to facilitate terminal sterilization by irradiation or gas. The company offers services such as development of individual SPS formulations meeting i …
  • North Pacific Bank,Ltd:企業の戦略・SWOT・財務情報
    North Pacific Bank,Ltd - Strategy, SWOT and Corporate Finance Report Summary North Pacific Bank,Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • AAC Technologies Holdings Inc. (2018):企業の財務・戦略的SWOT分析
    AAC Technologies Holdings Inc. (2018) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • MidAmerican Energy Co:電力:M&Aディール及び事業提携情報
    Summary MidAmerican Energy Company (MidAmerican Energy), a subsidiary of Berkshire Hathaway Energy, is a regulated electric and natural gas utility company that carries out the generation, transmission and distribution and selling of electricity. The company also undertakes distribution, selling and …
  • Singapore Telecommunications Ltd:企業の戦略・SWOT・財務分析
    Singapore Telecommunications Ltd - Strategy, SWOT and Corporate Finance Report Summary Singapore Telecommunications Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • BrightPath Early Learning Inc.:企業の戦略的SWOT分析
    BrightPath Early Learning Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆